Stories of Real VILTEPSO Patients and Caregivers

These are stories of real VILTEPSO patients and caregivers who are compensated spokespersons.

Ask your doctor if VILTEPSO would be right for you or your loved one.*

Real VILTEPSO Stories

Real VILTEPSO patients and caregivers share their heartfelt and inspiring stories of their journeys with Duchenne muscular dystrophy (DMD).

FEATURED STORY

Meet Jordan

Find out from Jordan’s mom Laura how he has had more than 300 infusions of VILTEPSO, and how he stays busy and keeps moving forward.

Learn about Jordan

Jordan
Roland

Roland

4 years old

Hear Roland’s parents and grandparents describe how Roland was able to start VILTEPSO soon after being diagnosed, and how he stays entertained during home infusions.

Watch Roland’s video Read his story »
Mason

Mason

11 years old

Hear how Mason gets his weekly infusions at home with a registered nurse, and listen to his mom Rebecca’s message of hope to other caregivers.

Watch Mason’s video Read his story »
Michael

Michael

14 years old

Hear Michael’s brothers describe how Michael views Duchenne as more of a special ability than a disability, and find out why taking VILTEPSO gives his parents hope for the future.

Watch Michael’s video Read his story »
Diego

Diego

19 years old

Hear Diego’s mom Leslie explain why she moved with her sons to the U.S. so Diego could get access to VILTEPSO, and how Diego continues to inspire her with his strength and positivity.

Watch Diego’s video Read his story »

*These stories describe unique experiences with VILTEPSO and are not intended to represent the average individual’s response. Individual patient results with VILTEPSO may vary.

Close

Learn about VILTEPSO’s efficacy data, and the four-year, open-label extension study

SEE EFFICACY & SAFETY DATA
Toggle ISI Open EXPAND

Indication

VILTEPSO is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 53 skipping. This indication is approved under accelerated approval based on an increase in dystrophin production in skeletal muscle observed in patients treated with VILTEPSO. Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial.

Important Safety Information

  • In clinical studies, no patients experienced kidney toxicity during treatment with VILTEPSO. However, kidney toxicity from drugs like VILTEPSO may be possible. Your doctor may monitor the health of your kidneys before starting and during treatment with VILTEPSO.
  • Common side effects include upper respiratory tract infection, injection site reaction, cough, and fever.
  • You are encouraged to report adverse events related to VILTEPSO. To do so, or for general inquiries, please call NS Pharma Medical Information at 1-866-NSPHARM (1-866-677-4276).

For more information about VILTEPSO, see full Prescribing Information.

For more information about VILTEPSO, see full Prescribing Information.